A synthetic astaxanthin finished product has reached the market with the release of ZanthoSyn, by Hawaiian firm Cardax.
Duffy MacKay of CRN argues that there is much in FDA's newly released New Dietary Ingredients draft guidance that represents a step forward for the industry.
Researchers in Spain observe the characterization and shelf-stability of astaxanthin from L. vannamei shrimp processing waste.
A recent FDA warning letter emphasizes the importance of maintaining consistent messaging about a product to avoid crossing the disease claims line.
Industry study suggests an increased tolerance of high-intensity training when study participants consumed the cordyceps-containing PeakO2 blend.